Search

Your search keyword '"Institute of Oncology"' showing total 36,021 results

Search Constraints

Start Over You searched for: Author "Institute of Oncology" Remove constraint Author: "Institute of Oncology"
36,021 results on '"Institute of Oncology"'

Search Results

101. Contemporary management of lymph node metastases from an unknown primary to the neck: I. A review of diagnostic approaches

102. Current trends in initial management of hypopharyngeal cancer: The declining use of open surgery

103. Proposal for a rational classification of neck dissections

104. Краниофациальная блок-резекция при злокачественных опухолях основания черепа

105. Tests for gene-environment interaction from case-control data: a novel study of type I error, power and designs This article is a US government work, and, as such, is in the public domain in the United States of America.

106. Occupational exposure to meat and risk of lymphoma: A multicenter case-control study from Europe

107. Chromosomal Localization of Four Human VH1-like Protein-Tyrosine Phosphatases

112. Mutational spectrum in a worldwide study of 29,700 families with BRCA1 or BRCA2 mutations

113. DNA glycosylases involved in base excision repair may be associated with cancer risk in BRCA1 and BRCA2 mutation carriers.

114. The prospect and challenges to the flow of liquid biopsy in Africa

116. Dynamic changes in circulating tumor <scp>DNA</scp> assessed by shallow whole‐genome sequencing associate with clinical efficacy of checkpoint inhibitors in <scp>NSCLC</scp>

117. Liver transplantation in metastatic colorectal cancer: are we ready for it?

118. A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF V600E-Mutant KRAS Wild-Type Metastatic Colorectal Cancer

119. Pembrolizumab plus Olaparib in Patients with Metastatic Castration-resistant Prostate Cancer: Long-term Results from the Phase 1b/2 KEYNOTE-365 Cohort A Study

120. Safety and efficacy of pralsetinib in RET fusion–positive non-small-cell lung cancer including as first-line therapy

121. Radium-223 for patients with metastatic castration-resistant prostate cancer with asymptomatic bone metastases progressing on first-line abiraterone acetate or enzalutamide: A single-arm phase II trial

122. Carm1-arginine methylation of the transcription factor C/EBPα regulates transdifferentiation velocity

123. Exploring the Immunogenicity of Noncanonical HLA-I Tumor Ligands Identified through Proteogenomics

124. Phase I/II sequencing study of azacitidine, epacadostat, and pembrolizumab in advanced solid tumors

125. Clinical activity of <scp>CC‐90011</scp> , an oral, potent, and reversible <scp>LSD1</scp> inhibitor, in advanced malignancies

126. Safety, pharmacokinetics, and antitumor activity of the anti-CEACAM5-DM4 antibody–drug conjugate tusamitamab ravtansine (SAR408701) in patients with advanced solid tumors: first-in-human dose-escalation study

127. First-in-human, open-label, phase 1/2 study of the monoclonal antibody programmed cell death protein-1 (PD-1) inhibitor cetrelimab (JNJ-63723283) in patients with advanced cancers

128. Durvalumab plus tremelimumab for the treatment of advanced neuroendocrine neoplasms of gastroenteropancreatic and lung origin

129. Evaluation of triple negative breast cancer with heterogeneous immune infiltration

130. Plain language summary of the updated results from the CROWN study comparing lorlatinib with crizotinib in people with advanced non-small-cell lung cancer

131. Targeting HER2-AXL heterodimerization to overcome resistance to HER2 blockade in breast cancer

132. ACT-Discover: identifying karyotype heterogeneity in pancreatic cancer evolution using ctDNA

133. Nirmatrelvir/ritonavir in COVID-19 patients with haematological malignancies

134. Challenges in oncology career: are we closing the gender gap? Results of the new ESMO Women for Oncology Committee survey

135. Circulating tumor DNA reveals complex biological features with clinical relevance in metastatic breast cancer

136. First-in-human study of JNJ-63709178, a CD123/CD3 targeting antibody, in relapsed/refractory acute myeloid leukemia

137. Lifestyle correlates of eight breast cancer-related metabolites: a cross-sectional study within the EPIC cohort

138. Advances in immune checkpoint inhibitor combination strategies for microsatellite stable colorectal cancer

139. Plasmatic BRAF-V600E allele fraction as a prognostic factor in metastatic colorectal cancer treated with BRAF combinatorial treatments

140. Immunotherapies against HER2-Positive Breast Cancer

141. Spleen tyrosine kinase/FMS-like tyrosine kinase-3 inhibition in relapsed/refractory B-cell lymphoma, including diffuse large B-cell lymphoma : updated data with mivavotinib (TAK-659/CB-659)

142. Therapy-Induced Senescence Enhances the Efficacy of HER2-Targeted Antibody–Drug Conjugates in Breast Cancer

143. Cabozantinib for previously treated radioiodine-refractory differentiated thyroid cancer: Updated results from the phase 3 COSMIC-311 trial

144. Patient-reported outcomes from the randomized phase 3 CROWN study of first-line lorlatinib versus crizotinib in advanced ALK-positive non-small cell lung cancer

145. Biomarkers of tumor-reactive CD4+ and CD8+ TILs associate with improved prognosis in endometrial cancer

146. Microfluidic-based dynamic BH3 profiling predicts anticancer treatment efficacy

148. Neoadjuvant eribulin in HER2-negative early-stage breast cancer (SOLTI-1007-NeoEribulin): a multicenter, two-cohort, non-randomized phase II trial

149. Co-benefits from sustainable dietary shifts for population and environmental health: an assessment from a large European cohort study

150. Robust imaging habitat computation using voxel-wise radiomics features

Catalog

Books, media, physical & digital resources